Huperzine A: A Comprehensive Reference
1. Identity and Chemical Characterization
Chemical Names and Formula
Huperzine A is a naturally occurring sesquiterpene alkaloid with the chemical formula C15H18N2O and a molecular weight of 242.32 g/mol, primarily isolated from the Chinese club moss Huperzia serrata. Its formal IUPAC name is (5R,9R,11E)-5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-5,9-methanocycloocta[β]pyridin-2-(1H)-one. Its CAS Registry Number is 103548-82-9.
Huperzine A is an alkaloid found in nature that is a member of the sesquiterpene chemical class, with a molar mass of roughly 242.32 g/mol. It has a bicyclic quinazoline ring made up of a pyrimidine ring in which two nitrogen atoms are fused within a benzene ring, completing a tetracyclic structure with a six-membered ring. The nitrogen atoms in the quinazoline ring provide potential hydrogen bonding sites that may aid in interactions with biological targets.
The biologically active form of greatest pharmaceutical interest is the naturally occurring optical isomer (−)-huperzine A, which is usually employed as a pharmaceutically active ingredient. An enantioselective synthesis is highly desirable, because (+)-huperzine A is significantly less potent than the natural (−)-antipode.
Botanical Source
Both huperzines were isolated from the toothed clubmoss (Huperzia serrata) that grows in eastern Asia. Huperzia serrata belongs to the family Huperziaceae. The plant grows in forests, shrubbery, and roadsides at altitudes of 300–2700 m.
Huperzine A also exists in other Huperzia species, including H. elmeri, H. carinat, and H. aqualupian, with varying quantities. For instance, Huperzia selago, a club moss distributed in Europe and North America, contains detectable levels of the alkaloid, albeit lower than in H. serrata. Higher yields have been reported in Phlegmariurus carinatus, a species from tropical regions, where Huperzine A content can exceed that of H. serrata, reaching up to 0.1% dry weight in some samples, making it a potential alternative source.
The content of Huperzine A in these plants is very low; for example, the highest content among the Huperzia genus is about 0.05 wt% based on the total weight of the plant. An investigation conducted in China between 1995 and 2001 demonstrated that the content of Huperzine A in Huperziaceae varies with harvest time and the region in which the plant is grown, ranging from approximately 46 µg/g to 133 µg/g. The growth cycle of Huperzia serrata is about eight to ten years, and extraction from natural sources is low-yielding, with an average yield of 0.011% from the dried herb, while overharvesting has caused a rapid decline in the abundance of Huperziaceae.
Other Natural Sources: Endophytic Fungi
(−)-Huperzine A is a competitive and reversible inhibitor of acetylcholinesterase. Research has identified HupA-producing endophytes, including Penicillium polonicum hy4 and Colletotrichum gloeosporioides Cg01, whose whole genomes have been sequenced and characterized to clarify the mechanism of HupA biosynthesis.
History of Isolation and Synthesis
(−)-Huperzine A, originally called (−)-selagine A, is a natural compound first reported in the literature in 1937 in an article by Polish researcher Piotr Oficjalski about the toxicity of alkaloids in the Lycopodiaceae family of mosses. Its structure, along with that of the similar alkaloid (−)-huperzine B, was reported in 1986 by Jia-Sen Liu and colleagues at the Chinese Academy of Sciences; both huperzines were isolated from the toothed clubmoss (Huperzia serrata) that grows in eastern Asia.
The first total artificial synthesis of Huperzine A in the laboratory was reported in 1989, both by a group of researchers in China and a group of researchers in the United States. (−)-Huperzine A tablets were launched in the Chinese market in 1995 and have been used for the treatment of Alzheimer's disease (AD) and memory disorders clinically.
Common Forms and Preparations
At present, Huperzine A is available in the market mainly as tablet or capsule, which must be given orally 2–3 times per day. In several countries, Huperzine A is sold as a dietary supplement for memory support. In China, Huperzine A is approved by the China Drug Administration (CDA) for the treatment of dementia. It is often marketed as a nootropic. A variety of manufacturers offer Huperzine A oral supplements in doses of 0.05 to 0.2 mg; clinical trials in dementia patients have used doses between 0.2 and 0.4 mg/day. For myasthenia gravis, healthcare providers have also given Huperzine A daily as a shot (intramuscular injection).
The plant contains mainly alkaloids, triterpenes, flavones, and phenolic acids. Four major structural classes of Lycopodium alkaloids have been described, including lycopodine, lycodine (to which Huperzine A belongs), fawcettimines, and others.
2. Traditional and Historical Use
The earliest record of medicinal usage of Qian Ceng Ta can be traced back to an ancient Chinese pharmacopeia, Ben Cao Shi Yi, which was written by Zangqi Chen in 739 AD during the Tang Dynasty. In that text, the herb was named Shi Song and was prescribed for relieving rheumatism, colds, relaxing muscles and tendons, and promoting blood circulation.
The same herb, with different names but similar usage prescriptions, can be found in Ben Cao Gang Mu by Shizhen Li in 1578 during the Ming Dynasty and Zhi Wu Ming Shi Tu Kao by Qijun Wu in 1848 during the Qing Dynasty.
H. serrata, belonging to the Lycopodiaceae family, has been used for centuries in the Chinese system of medicine for the treatment of fever, blood disorders, inflammation, and schizophrenia. Several members of the Huperziaceae (Huperzia and Phlegmariurus species) have been used as medicines in China for contusions, strains, swellings, schizophrenia, myasthenia gravis, and organophosphate poisoning.
Tea brewed from the leaves of Huperzia serrata was given to elderly people to alleviate their memory problems. This moss was valued for its purported ability to promote blood circulation, relieve pain, and address neurological ailments, reflecting a long-standing cultural reliance on natural remedies for age-related cognitive issues.
It is important to distinguish traditional use from scientific confirmation: the historical applications of Huperzia serrata encompassed a wide range of conditions from musculoskeletal pain to cognitive decline. The isolation of the specific active compound Huperzine A did not occur until the twentieth century, meaning all pre-modern use was of the whole plant preparation, not a standardized extract.
3. Key Constituents and Mechanisms of Action
Primary Active Compound
All the properties of H. serrata have been intensively studied in China, and most of the biological activity of H. serrata appears to be caused by the molecule Huperzine A. HupA is an unsaturated sesquiterpene alkaloid compound that effectively crosses the blood-brain barrier (BBB), acting as a mixed-competitive, reversible, and selective AChE inhibitor with a half-life of 5 h in the bloodstream, reaching a peak concentration at approximately 60 min in humans.
Acetylcholinesterase (AChE) Inhibition
The effects of this alkaloid have been attributed primarily to its ability to inhibit the cholinergic enzyme acetylcholinesterase (AChE), acting as an acetylcholinesterase inhibitor (AChEI). Huperzine A is a potent, highly specific, reversible acetylcholinesterase inhibitor, with IC50 binding affinity of approximately 82 nM. This inhibition leads to increased acetylcholine levels in synaptic clefts and enhanced cholinergic neurotransmission, which underlies its memory enhancement and neuroprotective effects.
The compound's preferential inhibition of the tetrameric AChE form (G4), along with excellent blood–brain barrier permeability and high oral bioavailability, distinguish it from conventional AChE inhibitors. Huperzine A targets different sites on acetylcholinesterase, and its inhibitory potency is eight- and twofold greater than donepezil and rivastigmine, respectively.
NMDA Receptor Antagonism
Huperzine A inhibits acetylcholinesterase, the enzyme responsible for breaking down the neurotransmitter acetylcholine (ACh), and is also a weak NMDA receptor antagonist with poor affinity. Its IC50 for NMDA receptor antagonism is approximately 65,000–82,000 nM (65–82 µM). Beyond acetylcholinesterase inhibition, huperzine A antagonizes N-methyl-D-aspartate (NMDA) glutamate receptors, thereby reducing excitotoxicity.
Excitotoxicity caused by disturbances of glutamatergic neurotransmission in the brain has been shown to be involved in the pathogenesis of Alzheimer's disease. NMDA receptor antagonists have been used as neuroprotective agents to ameliorate this process. Notably, (+)-huperzine A and (−)-huperzine A have been reported to antagonize the NMDA receptor with similar potency, although (+)-huperzine A is approximately 100-fold less potent than (−)-huperzine A in its ability to inhibit AChE. This finding indicates that some neuroprotective effects of the compound are not solely dependent on AChE inhibition.
Additional Neuroprotective Mechanisms
In addition to the symptomatic, cognitive-enhancing effect via inhibition of AChE, recent studies have reported that this drug has "non-cholinergic" effects on Alzheimer's disease. Most important among these is the protective effect of HupA on neurons against amyloid beta-induced oxidative injury and mitochondrial dysfunction, as well as via the up-regulation of nerve growth factor and antagonizing NMDA receptors.
HupA possesses the ability to protect cells against hydrogen peroxide, β-amyloid protein, glutamate, ischemia, and staurosporine-induced cytotoxicity and apoptosis. These protective effects are related to its ability to attenuate oxidative stress, regulate the expression of apoptotic proteins Bcl-2, Bax, P53, and caspase-3, protect mitochondria, upregulate nerve growth factor and its receptors, and interfere with amyloid precursor protein metabolism.
Huperzine A enhances gamma-aminobutyric acid (GABA)ergic signaling, contributing to anticonvulsant effects, and modulates nicotinic acetylcholine receptor signaling, which may mediate anti-inflammatory and neuroprotective actions by inhibiting nuclear factor kappa B (NF-κB) nuclear translocation. Additionally, huperzine A influences potassium currents and upregulates nerve growth factor and its receptors, further supporting neuroprotection.
The most recent discovery that HupA may reduce brain iron accumulation lends further support to the argument that HupA could serve as a potential disease-modifying agent.
Pharmacokinetics
Following a single 0.99 mg oral dose of an immediate-release formulation in healthy volunteers, the pharmacokinetics of HupA demonstrated an absorption half-life of 12.6 min, an elimination half-life of 288.5 min, a tmax of 79.6 min, a Cmax of 8.4 ng/mL, and an AUC of 4.1 ng/mL/min. Compared with tacrine, donepezil, and rivastigmine, HupA has better penetration through the blood-brain barrier, higher oral bioavailability, and longer duration of AChE inhibitory action.
Huperzine A has been shown to be highly bioavailable after oral supplementation in humans and to subsequently penetrate the blood-brain barrier, accounting for its ability to stimulate an "alert" electroencephalographic pattern.
4. Scientific Evidence by Area of Use
4.1 Alzheimer's Disease
Huperzine A, derived from the Chinese herb Huperzia serrata, was identified by scientists in China in the 1980s as a potent, reversible, selective inhibitor of AChE, which has a mechanism of action similar to donepezil, rivastigmine, and galantamine. (−)-Huperzine A tablets were launched in the Chinese market in 1995 and have been used for the treatment of Alzheimer's disease and memory disorders clinically.
2008 Cochrane Systematic Review: A Cochrane systematic review published in 2008 involving 6 randomized trials with 454 AD participants suggested that Huperzine A seemed to have some beneficial effects on AD; however, due to poor methodological quality and small sample size there was still insufficient evidence for a clinical recommendation.
2013 PLOS ONE Systematic Review and Meta-Analysis: Twenty RCTs including 1,823 participants were included. The methodological quality of most included trials had a high risk of bias. Compared with placebo, Huperzine A showed a significant beneficial effect on the improvement of cognitive function as measured by Mini-Mental State Examination (MMSE) at 8 weeks, 12 weeks, and 16 weeks, and by Hasegawa Dementia Scale (HDS) and Wechsler Memory Scale (WMS) at 8 weeks and 12 weeks. Activities of daily living favored Huperzine A as measured by Activities of Daily Living Scale (ADL) at 6 weeks, 12 weeks, and 16 weeks. One trial found Huperzine A improved global clinical assessment as measured by Clinical Dementia Rating Scale (CDR). However, the findings should be interpreted with caution due to the poor methodological quality of the included trials.
Phase II US Trial: One multicenter RCT assessed the safety, tolerability, and efficacy of Huperzine A in 210 patients with mild to moderate AD. Patients were randomized to receive placebo or Huperzine A (0.2 mg or 0.4 mg twice daily) for at least 16 weeks. A Phase 2 clinical trial reported that 0.4 mg twice per day, but not 0.2 mg twice per day, showed some benefit in patients with Alzheimer's disease.
One double-blind clinical study: One double-blind clinical study found that Huperzine A at a dose of 200 mcg twice a day produced measurable improvements in memory, cognitive function, and behavioral factors in 58% of AD patients, in contrast to 36% in the placebo group who showed improvement.
2016 Systematic Review of Systematic Reviews: In a 2016 systematic review of systematic reviews, Huperzine A was associated with a standardized mean difference of 1.48 (95% CI, 0.95–2.02) compared to placebo on measures of ADL among people with dementia, but the evidence was very low-quality and uncertain.
2022 Umbrella Review: In a 2022 umbrella review, Huperzine A was associated with broad benefits to dementia patients' cognitive functioning, but the degree of heterogeneity in measurements and outcomes of the reviewed studies indicated publication bias toward Huperzine A benefit.
Overall evidence strength for Alzheimer's disease: Though several clinical trials have examined the effect of Huperzine A on Alzheimer's patients, it is difficult to conclude whether it is effective. A published meta-analysis of 20 huperzine clinical trials leaves open the question of whether huperzine could be therapeutically useful. Trials reporting beneficial effects have tended to be small and of short duration. Longer and larger clinical trials with more rigorous methodology are needed to confirm the trends identified in past underpowered trials.
4.2 Vascular Dementia
In a double-blind, randomized, placebo-controlled (DBRPC) study of 78 patients with mild to moderate vascular dementia, those given Huperzine A 0.1 mg twice a day significantly improved in scores on the MMSE, clinical dementia rating, and activities of daily living (ADL) after 12 weeks (P<.01), with no significant adverse events.
Meta-analytic data indicate that Huperzine A outperforms donepezil in MMSE improvements specifically for vascular dementia, highlighting its neuroprotective benefits in cerebrovascular contexts. A 2014 meta-analysis that included 2 vascular dementia trials alongside 8 AD trials found significant benefits for both conditions.
Phase IV clinical trials in China demonstrated that HupA significantly improved memory deficits in elderly people with benign senescent forgetfulness and patients with Alzheimer's disease and vascular dementia, with minimal peripheral cholinergic side effects and no unexpected toxicity.
However, a Cochrane review found only one clinical trial meeting inclusion criteria, in which no difference compared with placebo was found for vascular dementia. Evidence for this indication therefore remains limited and inconsistent.
4.3 Mild Cognitive Impairment (MCI)
A separate attempt to evaluate clinical trials of Huperzine A for mild cognitive impairment found no studies that met inclusion criteria for meta-analysis, that is, randomized, parallel-group, placebo-controlled trials. No trials have yet tested Huperzine A in patients with mild cognitive impairment (as of the most recent Cochrane search). Evidence for this indication is therefore currently absent at the level of qualifying RCTs.
4.4 Memory Enhancement in Healthy Individuals
A controlled trial involving 34 pairs of matched healthy adolescent students found that Huperzine A capsules at 100 mcg twice daily enhanced memory and learning performance over four weeks, as measured by standardized cognitive tests. These findings suggest cholinergic modulation may enhance cognitive performance in healthy young people, though the small sample size and limited duration mean larger randomized trials are needed before drawing firm conclusions.
4.5 Traumatic Brain Injury (TBI)
A 12-week study of 14 people in the United States with moderate or severe traumatic brain injuries found that Huperzine A did not improve memory performance compared to placebo. The dose was escalated every four days from 100 mcg in the mornings to 200 mcg twice daily to 300 mcg twice daily. Notably, those taking placebo improved more than those taking Huperzine A, although the difference was not statistically significant. Evidence for TBI is preliminary and currently negative.
4.6 Myasthenia Gravis
Initial clinical studies with Huperzine A conducted in China, which first focused on its use in myasthenia gravis, showed considerable benefit in the treatment of dementia. According to one preliminary clinical study with 128 patients, Huperzine A was reported to alleviate muscle weakness in myasthenia gravis patients. Although this is only one study, it offers promising results that will hopefully be followed up on and confirmed by additional clinical studies. Early research suggests that giving Huperzine A intramuscularly for 10 days may prevent muscle weakness in patients with myasthenia gravis and may have equal or longer-lasting effects compared to intramuscular neostigmine. Evidence for this indication is limited to small, early-stage studies.
4.7 Organophosphate Poisoning and Nerve Agent Exposure
HupA can also be used as a protective agent against organophosphate intoxication. In contrast to pyridostigmine, Huperzine A crosses the blood-brain barrier and, therefore, may be effective in preventing seizures and other neuropathology caused by soman. Animal experiments have demonstrated activity against soman-induced seizures and mortality; however, clinical studies are lacking. This area of research remains at the preclinical stage in terms of human data.
4.8 Epilepsy and Anticonvulsant Activity
Huperzine A enhances GABAergic signaling, contributing to anticonvulsant effects. Anticonvulsant activity of Huperzine A has been demonstrated in mice, and a pilot clinical study has been undertaken. A dose escalation study in patients with drug-resistant epilepsy was conducted to investigate the safety and tolerability of an immediate-release formulation of Huperzine A; in this study, patients experienced dose-limiting adverse events of nausea and vomiting, many within the first 31 hours, most probably due to rapid plasma exposure from the immediate-release formulation. Evidence in epilepsy remains very preliminary.
5. Body Systems and Health Areas
- Central Nervous System / Neurological: The effects of this alkaloid have been attributed to its ability to inhibit the cholinergic enzyme acetylcholinesterase. Its role in neuroprotection appears to make it a good therapeutic candidate for Alzheimer's disease.
- Cognitive Function and Memory: As a potent and reversible inhibitor of acetylcholinesterase (AChE), an enzyme that breaks down the neurotransmitter acetylcholine, it increases acetylcholine levels in the brain, supporting cognitive functions such as memory and learning.
- Neuromuscular Junction: Huperzine A's prolongation of acetylcholine availability at neuromuscular junctions underlies its investigated use in myasthenia gravis, a neuromuscular disorder.
- Mitochondrial Function: It protects mitochondrial functions from the toxic effects of amyloid beta both in vitro and in vivo.
- Oxidative Stress: Huperzine A exhibits antioxidant properties by reducing reactive oxygen species and oxidative stress in neuronal models.
- Neuroinflammation: Huperzine A has been shown to have neuroprotective qualities including lowering oxidative stress, lessening mitochondrial dysfunction, and controlling neuroinflammation.
- Excitotoxicity / Glutamatergic System: By antagonizing NMDA receptors, Huperzine A reduces glutamate-induced excitotoxicity in neuronal cultures and animal models. These neuroprotective mechanisms have been consistently demonstrated at molecular and cellular levels in multiple in vivo and in vitro studies.
- Iron Metabolism in the Brain: Long-term treatment with Huperzine A significantly reduces iron content and transferrin receptor 1 expression in the brains of transgenic Alzheimer's disease mice, and promotes the proliferation of cultured mouse embryonic hippocampal neural stem cells.
6. Dosage Forms and Reported Dosages
Huperzine A has been administered to healthy volunteers and patients in numerous trials, many in China, demonstrating acceptable safety and tolerability as well as efficacy in Alzheimer's disease, benign senescent forgetfulness, vascular dementia, myasthenia gravis, schizophrenia, and cocaine dependence. The dosages used in these trials were between 0.01 and 0.8 mg/day via oral administration or intramuscular injection.
The following dosages are those reported in specific studies and review sources:
- For Alzheimer's disease and vascular dementia: doses of 50–200 mcg of Huperzine A twice daily.
- A Phase 2 clinical trial used 0.4 mg twice per day and 0.2 mg twice per day, with only the higher dose showing some benefit in patients with Alzheimer's disease.
- For age-related decline in thinking skills (senile or presenile dementia): doses of 30 mcg twice daily have been used in studies.
- For improving memory in adolescents: doses of 100 mcg twice daily were used in a controlled trial.
- In clinical trials, daily oral doses of 300–400 µg Huperzine A reduced memory and cognitive deficits in individuals diagnosed with Alzheimer's disease and age-associated cognitive decline.
- At higher doses, Huperzine A has been shown to reduce memory impairment, but there was also a dose-dependent increase in side effects, with approximately 50% of patients in one study showing side effects at the 1,200 µg/day dose.
- In a DBRPC study of vascular dementia: 0.1 mg twice a day for 12 weeks.
- In a US TBI trial: the dose was escalated from 100 mcg in the mornings to 200 mcg twice daily to 300 mcg twice daily, increasing every four days, over 12 weeks.
Huperzine A is available in the market mainly as tablet or capsule, which must be given orally 2–3 times per day. The pharmacokinetic parameters of Huperzine A make it difficult to optimize both efficacy and safety with current oral formulations.
7. Safety Considerations and Drug Interactions
Adverse Effects Observed in Clinical Trials
In clinical trials, cholinergic adverse reactions have been noted, including hyperactivity, nasal obstruction, nausea, vomiting, diarrhea, insomnia, anxiety, dizziness, thirst, and constipation. Some side effects identified in clinical trials include tachycardia, bradycardia, headache, intense dreams, muscle cramps, and arthralgia at high doses.
One trial reported abnormalities in electrocardiogram (ECG) patterns, including cardiac ischemia and arrhythmia. Drug-induced liver injury has been reported. Huperzine A may present with mild cholinergic side effects such as nausea, vomiting, and diarrhea. Slight muscle twitching and slurred speech might also occur, as well as hypersalivation and sweating.
Studies showed a favorable safety profile; in some studies, transient dose-related nausea occurred at the higher dose levels.
Acute Toxicology
The acute oral median lethal dose of Huperzine A in rats has been reported as 4.6 mg/kg and as an intravenous dose of 0.63 mg. No pathological changes were found in histological studies of the liver, kidney, heart, lungs, or brain after 180 days of administration, and no mutagenicity or teratogenicity were found in rodent studies. Symptoms of acute toxicity are similar to those of other cholinergic inhibitors and include muscular tremor, drooling, tears, increased bronchial secretions, and incontinence.
Gastrointestinal Adaptation
One encouraging finding from animal research is that gastrointestinal side effects appear to fade with continued use. After single doses, Huperzine A noticeably affected gut enzyme activity and motility in mice, but after 7 or 28 consecutive daily doses, those changes disappeared, suggesting the digestive system adapts relatively quickly.
Cardiovascular Considerations
Because acetylcholine slows heart rate, any substance that increases it raises a reasonable concern about cardiovascular safety. Depressed heart rate (bradycardia) has been listed among the cholinergic side effects in clinical trial reports, though it occurs at low rates. Contraindications include pre-existing conditions such as bradycardia (slow heart rate), peptic ulcers, and seizure disorders, as Huperzine A could exacerbate these conditions given its mechanism of action.
Pregnancy and Lactation
The use of Huperzine A during pregnancy and lactation is not recommended due to the lack of sufficient safety data.
Long-Term Safety Data
Huperzine A appears safe for short-term use, but evidence for long-term safety is lacking. The longest well-documented continuous use is 24 weeks (about six months).
Drug Interactions
Because it acts as an acetylcholinesterase inhibitor, Huperzine A can potentially interact with many drugs including other anticholinergic drugs, dopamine D2 receptor blockers, calcium channel blockers, and beta adrenergic receptor antagonists.
The following interaction categories have been identified:
- Cholinesterase inhibitors (additive/synergistic risk): Huperzine A can potentiate the effects of other cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, commonly used in Alzheimer's treatment. This combination can amplify side effects like gastrointestinal distress and dizziness.
- Anticholinergic drugs (opposing effects): Huperzine A works in direct opposition to anticholinergic medications, potentially reducing their effectiveness.
- Beta-blockers: Huperzine A may interact with beta-blockers such as atenolol, metoprolol, or propranolol, which are medicines used for certain heart conditions or to lower blood pressure.
- Cholinergic agents: Huperzine A may interact with cholinergic agents such as bethanechol, carbachol (Miostat), or pilocarpine.
- Cholinergic supplements: Huperzine A may interact with supplements that raise acetylcholine levels, such as alpha-GPC, citicoline, or acetyl-L-carnitine, increasing cholinergic activity and the risk of adverse effects. Huperzine A should not be taken with other cholinergic supplements without carefully monitoring each person's response.
Peptic Ulcer and Gastrointestinal Conditions
People with peptic ulcers or acid reflux conditions should be cautious, since increased cholinergic activity can stimulate gastric acid secretion, though the evidence suggests GI effects diminish with repeated dosing.
Regulatory Status
HupA is a licensed anti-Alzheimer's disease drug in China and is available as a nutraceutical in the US. In the United States, the FDA has not reviewed Huperzine A for safety and effectiveness.
References
Go back